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1. Introduction 
The gut mucosal immune system has to maintain an intricate immune homeostasis by 
maintaining tolerance to macronutrients, commensal flora, and other harmless molecules 
in the gut lumen while exerting effective immune defense against pathogenic microbes. It 
takes the first few years of life to establish this intricate immune homeostasis and until 
then the gut mucosal immune system is rather error-prone. This is reflected in the fact 
that young infants and children often suffer from temporary intolerance to common food 
proteins (FP), e.g. food allergy (FA). During this period, most FA manifests as delayed 
type FA, mediated by cellular immune responses – often called FP induced enterocolitis 
syndrome (FPIES) (Jyonouchi, 2008; Nowak-Wegrzyn and Muraro, 2009; Sicherer et al., 
1998). Although FPIES seldom cause fatal anaphylaxis, as opposed to IgE-mediated FA, 
this condition is often under-diagnosed and under-treated. This is, in part, due to the 
delayed onset of symptoms that renders clinical connection more difficult, as well as, the 
lack of commercially available diagnostic measures. This is in contrast to IgE mediated FA 
in which a causal relationship is apparent in many cases and reactivity to food allergens is 
easily detected with prick skin test (PST) and/or presence of FA specific IgE antibody. 
The delay in the onset of symptoms of FPIES makes it especially difficult to diagnose 
FPIES clinically in infants and young children, as well as those with limited expressive 
language including children with autism spectrum disorders (ASD). In general, FPIES has 
an excellent prognosis provided there is timely implementation of avoidance measures 
against offending food (Jyonouchi, 2008; Nowak-Wegrzyn and Muraro, 2009). However, 
delayed diagnosis/treatment of FPIES can lead to failure to thrive (FTT), protein losing 
enteropathy, and possibly other irreversible complications. 
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GI symptoms are frequently observed in ASD (Buie et al., 2010). A role of FPIES has been 
suspected to play a role in GI symptoms observed in ASD children, since many parents of 
ASD children with GI symptoms report favorable responses to the casein-free, gluten-free 
(cf/gf) diet. We have reported previously that FPIES accounts for the GI symptoms 
experienced in many young ASD children (Jyonouchi et al., 2005). We have also observed 
that resolution of GI symptoms in ASD/FPIES children following implementation of 
avoidance of offending food was associated with improvement of certain behavioral 
symptoms, (Jyonouchi H, 2007).  
However, in our observation, even after recovering from FPIES, some ASD children 
continue to suffer from recurrent or persistent GI symptoms. We also observed that flare 
ups of GI symptoms in these ASD/FPIES children are usually triggered by GI insults such 
as microbial gastroenteritis and prolonged oral antibiosis. Such ‘treatment-resistant’ GI 
symptoms after implementation of appropriate avoidance measures are less frequently 
observed in non-ASD/FPIES children. Since diagnosis of FPIES in ASD children are 
typically delayed partly due to their limited expressive language, it may be argued that this 
is simply reflecting a longer period of GI inflammation in ASD/FPIES children than in non-
ASD/FPIES children. However, ASD/FPIES children with persistent GI symptoms also 
often exhibit other co-morbid conditions such as recurrent respiratory infection, adverse 
reaction to multiple medications, and seizure disorders, in our observation. Thus we 
hypothesized that 1) oral tolerance to FP and commensal flora is fragile and easily broken in 
ASD/FPIES children with persistent GI symptoms, and 2) this is associated with altered 
innate immune and adaptive immune responses in these ‘treatment-resistant’ ASD/FPIES 
children. We also hypothesized that evidence of impaired oral tolerance can be detected by 
studying peripheral blood mononuclear cells (PBMCs). These hypotheses are based on the 
facts that 1) aberrant immune responses to commensal flora is implicated with onset of 
chronic inflammatory conditions in the gut (Schirbel and Fiocchi, 2010), 2) plasticity of T-
helper (Th) cell differentiation is not as definite as initially thought and aberrant innate 
immune responses and altered gut microbiota can hinder development of gut immune 
homeostasis (Lee and Mazmanian, 2010; Zhou et al., 2009), and 3) FP specific Th cells 
circulate in the peripheral blood (PB) (Karlsson et al., 2004).  
This study focused on ASD/FPIES children and non-ASD/FPIES children who have already 
been treated for FPIES. In these subjects, we assessed innate immune responses, Th cell 
polarization, and T cell functions in comparison with normal control children. Our results 
indicate that a subset of ASD/FPIES children with persistent GI symptoms revealed a 
different pattern of innate and adaptive immune responses as compared to both ASD/FPIES 
or non-ASD/FPIES children. 
2. Materials and methods 
2.1 The study subjects 
The study subjects were recruited following the study protocols approved by the 
Institutional Review Board, University of Medicine and Dentistry of New Jersey-New Jersey 
Medical School (UMDNJ-NJMS). Blood samples were collected after obtainment of signed 
parental consent forms. Signed assent forms were also obtained, if applicable, in children 
older than 7 years of age.  
A total of 45 ASD/FPIES children who have been treated for FPIES were included in this study 
in addition to control ASD/non-FPIES (N=24), non-ASD/FPIES (N=26), and typically 
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growing, healthy control children without FPIES (N=43). Among 45 ASD/FPIES children, 16 
children revealed persistent or recurrent GI symptoms with suboptimal responses to dietary 
intervention measures (avoidance of offending food). These children are categorized as ASD-
immune subtype (ASD-IS), since their behavioral and GI symptoms flared up repeatedly 
following immune insults such as viral infection. The demographics of the study subjects are 
summarized in Table 1. Non-ASD/FPIES children recruited to the study were also already 
treated for FPIES with implementation of appropriate avoidance measures. ASD and FPIES 
children were recruited in the Pediatric Allergy/Immunology Clinic at our institution. Normal 
healthy control and ASD/non-FPIES children were recruited in the Subspecialty Clinic at 
UMDNJ-NJMS where subspecialties include allergy/immunology, cardiology, developmental 
pediatrics, endocrinology, genetics, gastroenterology, nephrology, pulmonology, and general 
pediatrics. In most cases, blood samples were obtained when they were medically indicated to 
have venipuncture for routine blood work or general health screening. At the time of sample 
obtainment, all the subjects were examined to ensure absence of active infection. 
 
 
Age (yr) 
median (range) 
Sex (male: female) Ethnicity 
ASD-IS (N=16) 
9.7 (5-15.9) 16 : 0 
13 W, 1 AA, 1 
mixed, 1 Asian 
ASD/FPIES (N=29) 
6.2 (3-17.3) 25 : 4 
24 W, 1 AA, 1 
mixed, 3 Asians 
ASD/non-FPIES (N-24) 
6.5 (3-15.9) 20 : 4 
16 W, 1 AA, 2 
mixed, 5 Asians 
Non-ASD/FPIES (N=26) 
4.2 (1.7-15.9) 17 : 9 
22 W, 2 mixed, 2 
Asians 
Normal control (N=43) 
 
8.5 (1-17.8) 29 : 14 33 W, 6 AA, 4 mixed 
1Abbreviations used: AA (African Americans), W (Caucasians)  
Table 1. Demographics of the pediatric study subjects. 
2.1.1 ASD diagnosis 
ASD diagnosis was made or ascertained by DSM-IV (Diagnostic and Statistical Manual of 
Mental Disorders IV) criteria, ADI-R (Autism Diagnostic Interview-Revised), and/or ADOS 
(Autism Diagnostic Observational Schedules).  All the ASD children recruited to this study 
were those with established autism diagnosis from established autism diagnostic centers 
including ours at UMDNJ.  
2.1.2 Diagnosis of atopic disorders 
Allergic rhinitis (AR), allergic conjunctivitis (AC) were diagnosed with positive prick skin 
test reactivity and/or presence of allergen-specific IgE accompanied by clinical features 
consistent with AR and AC (Butrus and Portela, 2005; Nassef et al., 2006). Asthma diagnosis 
was based on NIH guideline criteria (National Heart, Lung, Blood Institute, 2007). Asthma 
without prick skin test reactivity and/or allergen-specific IgE antibody was categorized as 
non-atopic asthma (Nassef et al., 2006)  
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2.1.3 Diagnosis of FPIES 
FPIES to common food proteins (FPs; cow’s milk protein, wheat, and soy) was diagnosed 
using the following diagnostic criteria: 1) presence of objective GI symptoms (diarrhea, loose 
stool, and constipation) which resolved with avoidance of causative FPs (Sicherer and 
Sampson, 2006), 2) delayed (more than 6 h) onset of GI symptoms following exposure to 
offending FPs after resolution of GI symptoms, and 3) cellular immune reactivity to 
offending FPs defined as the production of more than 1 standard deviation (SD) + control 
mean value of TNF-ǂ and/or IL-12 by PBMCs with stimuli of causative DPs (Jyonouchi et 
al., 2005).   
Diagnoses of other GI conditions were ascertained by reviewing medical charts and 
previous laboratory findings.  Persistent GI symptoms are defined as lack of complete 
resolution of GI symptoms following introduction of appropriate restricted diet (avoidance 
of offending food) with persistent unformed stools, loose stool, and constipation alternating 
with diarrhea or loose stool.  It is of note that these ASD/FPIES children with persistent GI 
symptoms (e.g. ASD-IS children) often revealed beneficial effects from oral anti-fungal 
medications (fluconazole or nystatin) and antibiotics (usually metronidazole) with 
improvement of GI symptoms.  However, the beneficial effects of anti-fungals and 
antibiotics are generally short-lived and repeated courses of these therapies are often 
required, along with the persistent use of probiotics to control GI symptoms. 
2.2 Cultures of PBMCs  
PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation.  Innate immune 
responses were assessed by incubating PBMCs (106 cells/ml) overnight with TLR4 agonist 
(LPS; 0.1 µg/ml, GIBCO-BRL, Gaithersburg, MD), TLR2/6 agonist (zymosan; 50 µg/ml, 
Sigma-Aldrich, St. Luis, Mo), TLR3 agonist (Poly I:C, 0.1 µg/ml, Sigma-Aldrich), and 
TLR7/8 agonist (CL097, water-soluble derivative of imidazoquinoline, 20 µM, InvivoGen, 
San Diego, CA) in RPMI 1640 with additives as previously described (Jyonouchi et al., 2001).  
Overnight incubation was adequate to induce the optimal responses in this setting.  Levels 
of proinflammatory [tumor necrosis factor-ǂ (TNF-), interleukin (IL)-1, IL-6, IL-12p40, 
and IL-23] and counter-regulatory [IL-10, transforming growth factor-ß (TGF-ß) and soluble 
TNF receptor II (sTNFRII)] cytokines in culture supernatant were then measured by an 
enzyme-linked immunosorbent assay (ELISA).   
Cellular reactivity to T cell stimulants was assessed by incubating PBMCs (106 cells/ml) 
with T cell mitogens [Con A (2 µg/ml) and PHA (5 µg/ml)], recall antigens (Ags)[soy 
protein (100 µg/ml), ß-lactoglobulin (ßLG; 10 µg/ml) Sigma-Aldrich, candida Ag (5 µg/ml), 
dust mite (5 µl/ml) Greer, Lenoir, NC, tetanus toxoid (1:5000)], and IFN-Ǆ inducing 
cytokines [IL-12p70 (0.2 ng/ml, BD Biosciences, San Diego, CA), IL-18 (1 ng/ml, BD 
Biosciences) for 4 days and measuring levels of IFN-, TNF-ǂ, IL-5, IL-10, IL-12p40, and IL-
17 in the culture supernatant (Jyonouchi et al., 2005).  Initial titration studies showed that a 
four day incubation period resulted in the optimal production of these cytokines, in this 
setting.   
Cytokine levels were measured by ELISA, using OptEIA™ Reagent Sets (BD Biosciences) for 
IFN-Ǆ, IL-1ß, IL-5, IL-6, IL-10, IL-12p40, and TNF-ǂ, and ELISA reagent set (R & D, 
Minneapolis, MN) for sTNFRII, IL-17 (IL-17A), and TGF-ß. IL-23 ELISA kit was purchased 
from eBiosciences, San Diego, CA.  Intra- and inter-variations of cytokine levels were less 
than 5%.  
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2.3 Flow cytometry   
For intracellular cytokine staining in CD4+ T cells, the following fluorochrome-conjugated 
monoclonal antibodies were used: CD4-PerCp, IFN-Ǆ-PE-Cy7, IL-17-PE, IL-4-FITC, IL-10-
Pacific Blue (all from eBiosicences), and TGF-ß-APC (R & D, Minneapolis, MN).  PBMCs 
were incubated at 37oC overnight (16 h) with medium alone, Staphylococcal enterotoxin B (5 
µg/mL, Sigma-Aldrich), or candida Ag (5 µg/ml, Greer) in the presence of Brefeldin A 
(BFA; 5 µg/ml, Sigma-Aldrich), anti-CD28 (1 µg/ml, eBiosciences), and anti-CD49 (1 µg/ml, 
eBiosciences). The same culture medium used for the cytokine production assay was 
utilized.  Then PBMCs were permeabilized (permeabilization buffer, BD Biosciences) and 
stained with the above described antibodies.  All flow cytometry was conducted by using 
FACSVantage SE TM (BD Biosciences) and the data were analyzed with the CellQuest 
software (BD Biosciences) and FlowJo (TreeStar, Ashland, OR).  
2.4 Transcription profiling 
PB monocytes were purified using an immuno-affinity column following the company’s 
instructions (MACS monocytes isolation kit, Miltenyi Biotec, Auburn, CA).   Total RNA 
were extracted by the RNA easy kit (Quiagen , Valencia, CA). RNA labelling and 
hybridizations on Agilent Human 4x44K arrays (Agilent, Lexington, MA) were done using 
the Agilent One-Color Microarray-Based Gene Expression Analysis Ver 5.5 protocol 
(Agilent).  All slides were scanned by an Agilent Scanner and normalized numerical data 
were obtained by Agilent Feature extraction software 9.5. 
2.5 Statistical analysis  
For comparison of test values with control values, a Wilcoxon signed rank test was used.  
For comparison of values of multiple groups, a Kruskall-Wallis test was used. A Chi square 
(χ2) test was used to examine the difference in frequency. These tests were performed using 
R.2.10.1 (R-Development Core Team 2009).  A p value of <0.05 was considered to be 
statistically significant.  For the analysis of microarrays experiments, Gene Spring GX v11 
software (Agilent) was used.  After filtering for “present” calls in at least 20% of samples, 
fold change analysis were performed for group for comparisons on 26992 probes. Genes 
with at least two fold changes, as compared to controls, are determined to be either up-
regulated or down-regulated.  Using a specific module of GeneSpring software (Agilent), 
pathways enrichment analysis on those genes was performed to see if there is a statistically 
significant enrichment (p<0.05) for specific BioPax pathways. 
3. Results 
3.1 Clinical features 
Prevalence of common childhood disorders in the study groups is shown in Table 2.  The 
prevalence of allergic rhinoconjunctivitis and asthma in ASD-IS, ASD/FPIES, ASD/non-
FPIES, as well as in non-ASD/FPIES children was found to be similar to what is reported in 
general population (Table 2) (Akinbami et al., 2011; Singh et al., 2010).  However, ASD-IS 
children revealed a higher prevalence of recurrent infection [recurrent otitis media (ROM) 
and chronic rhinosinusitis (CRS)] than other study groups (Table 2).  It is of note, that 3 
subjects out of these 6 ASD-IS children with recurrent infection were diagnosed with 
specific polysaccharide antibody deficiency (SPAD).  In contrast, non-ASD/FPIES children 
seldom revealed chronic infection.  Around 10% of ASD/FPIES and ASD/non-FPIES 
children had history of ROM but they did not suffer from CRS and they are responsive to 
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the first-line antibiotics such as amoxicillin.  It remains to be seen whether apparent higher 
prevalence of ROM in the ASD children in our study is associated with under-diagnosis or 
under-treatment, secondary to their limited expressive language. 
 
 AR+AC Asthma ROM/CRS 
Seizure 
disorders 
ASD-IS 
(N=16) 
4 (25.0%) 3 (18.8%)4 62 (37.5%) 2 (12.5%) 
ASD/FPIES 
(N=29) 
4 (13.8%) 3 (10.3%) 43 (13.8%) 1 (3.4%) 
ASD/non-FPIES 
(N=24) 
5 (20.8%) 2/24 (8.3%) 2 (8.3%) 0 
Non-ASD/FPIES 
(N=26) 
6 (23.1%) 3/26 (11.5%) 1 (0.4%) 0 
Normal control 
(N=43) 
8 (18.6%) 5 (11.6%) 0 0 
1Abbreviations used: AR+AC, allergic rhinoconjunctivitis, ROM, recurrent otitis media, CRS, chronic 
rhinosinusitis 
2Among 6 subjects with recurrent ROM and CRS, 3 subjects were diagnosed with specific 
polysaccharide antibody deficiency (SPAD). 
3One patient was diagnosed with SPAD. 
4All 3 asthma patients are diagnosed with SPAD and asthma is considered as non-atopic asthma 
triggered by infection. 
Table 2. Prevalence of co-morbid condition in the study subjects. 
3.2 Innate immune responses 
In response to a TLR4 agonist (LPS), ASD/FPIES PBMCs revealed lower TNF-ǂ and IL-12 
production than normal controls (Fig. 1). Non-ASD/FPIES PBMCs also revealed similar 
tendencies, however, the ASD/non-FPIES and ASD-IS cells did not differ from normal 
controls in the production of these cytokines (Fig. 1).  IL-23 production with a TLR4 agonist 
 
 
Fig. 1. Production of TNF-ǂ and IL-12 by PBMCs (106 cells/ml) from the study groups 
following overnight incubation with a TLR4 agonist (LPS). *; lower than normal controls by 
Wilcoxon signed rank test. 
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was lower in both the ASD-IS and ASD/FPIES groups than normal controls (Fig. 2).  We 
also observed lower production of IL-12 (with a TLR9 agonist) and IL-1ß (in the absence of 
stimuli and with a dectin 1 agonist) in the ASD-IS group.  This was not observed in any 
other study groups (Figs. 2-3).  IL-6 production without stimuli and in response to a TLR9 
agonist were also the lowest in the ASD-IS group (Fig.3).  ASD/FPIES but not non-
ASD/FPIES PBMCs revealed a similar tendency.  However, this was less evident than in the 
ASD-IS cells (Fig. 3).  Non-ASD/FPIES PBMCs revealed higher TGF-ß production with a 
TLR2/6 agonist than normal controls (Fig. 3). Taken together, our results indicate that ASD-
IS, ASD/FPIES, and non-ASD/FPIES children reveals different patterns of cytokine 
production in response to TLR agonists. 
 
 
Fig. 2. Production of IL-23, IL-12, and IL-1ǃ by PBMCs (106 cells/ml) in responses to TLR 
agonists as shown in the figure. *; significantly lower than normal controls by Wilcoxon 
signed rank test.  IL-1ǃ production was obtained when cells were cultured in the medium 
without a stimulus. 
 
 
Fig. 3. Production of IL-6, IL-1ǃ, and TGF-ǃ by PBMCs (106 cells/ml) when incubated 
overnight with medium only (IL-6), TLR9 agonist (IL-6), Dectin-1 agonist (D1 – IL-1ǃ), and 
TLR2/6 agonist (TGF-ǃ). *; significantly lower as compared to normal controls by Wilcoxon 
signed rank test .   **; significantly higher than normal controls by Wilcoxon signed rank 
test. 
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3.3 Adaptive immune responses  
No significant differences were observed among the study groups in responses to stimuli of 
T cell mitogens or recall antigens via vaccination (tetanus toxoid) or respiratory tract (dust 
mite). However, when PBMC responses to gut luminal Ags were tested, we observed a 
higher IL-5 production (with candida Ag) in non-ASD/FPIES children, while IL-17 
production with ß-LG and candida Ag were higher in the ASD-IS group as compared to the 
non-ASD/FPIES group (Fig. 4).  Such increase in IL-17 production was not observed in 
ASD/FPIES children (Fig. 4).  Moreover, IL-10 production was lower in the ASD-IS children 
without stimuli as well as in response to candida Ag (Fig. 5).  We also assessed frequency of 
Th cell subsets following stimulation of PBMCs with a polyclonal T cell stimulant (SEB) 
overnight by measuring intracellular expression of Th-lineage specific cytokines in CD4+ T 
cells. Both the ASD-IS and ASD/FPIES groups revealed a lower frequency of IFN-Ǆ+ Th1 
cells than controls (Fig. 6). Frequency of IL-17+ Th17 cells were also lower in the ASD/FPIES 
group but not in ASD-IS or non-ASD/FPIES children.  Our results also indicated differences 
in T cell responses in the study groups. 
 
 
Fig. 4. Production of IL-5 and IL-17 in response to gut luminal antigens as shown in Figure. 
ǃLG; ǃ-lactoglobulin. PBMCs (106 cells/ml) were incubated for 4 days with these luminal 
antigens.  **; significantly higher than normal controls by by Wilcoxon signed rank test.  ***; 
significantly higher than non-ASD/FPIES, ASD/non-FPIES, ASD/FPIES controls by 
Wilcoxon signed rank test. 
3.4 Transcription profiling results 
Transcript profiles of PB monocytes were tested in 16 ASD-IS, 14 ASD/FPIES, 16 ASD/non-
FPIES, and 26 normal control children. The changes of transcript expression are summarized 
in Table 3.  As compared to ASD/FPIES, ASD/non-FPIES, and normal control groups, ASD-
IS PB monocytes revealed that a large numbers of genes are up- or down-regulated over 2-
fold and the difference was most significant when compared to normal controls (Table 3). 
ASD/FPIES children also revealed changes in gene expression as compared to ASD/non- 
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Fig. 5. IL-10 production when PBMCs (106 cells/ml) were cultured for 4 days with candida 
Ag or medium only in the study groups. *; significantly lower than normal controls by 
Wilcoxon signed rank test. 
 
 
Fig. 6. Percent of IFN-Ǆ+ and IL-17+ CD4+ T-helper cells per total CD4+ cells in PBMCs 
obtained from the study groups.  PBMCs were incubated overnight with SEB and 
intracellular cytokine expression was assessed by flow cytometry as detailed in the 
Materials and Methods section.  *; lower than normal controls by Wilcoxon signed rank test. 
FPIES and normal controls.  However, the numbers of genes up- or down-regulated were not 
as many as seen in ASD-IS children (Table 3).  ASD/non-FPIES children also revealed changes 
in gene expression in a large number of genes as compared to controls (Table 3).  Notable 
findings are the down-regulated expression of cytokines and chemokines in ASD-IS, as well as 
ASD/FPIES children, as compared to ASD/non-FPIES children.  This finding is consistent 
with those from the bioassays. CCL7 expression was down regulated in ASD/non-FPIES 
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children as compared to all the study groups. The pathway analysis did not reveal any 
significant enrichment of genes in known signaling pathways.  GO analysis revealed 
significant differences in the ASD/FPIES and ASD/non-FPIES groups; changes were evident 
in inflammatory processes and cytokine/chemokine signaling pathways. In comparison with 
normal controls, both ASD-IS and ASD/FPIES patients did not reveal significant changes.  
 
Group 
Numbers of genes Up-
regulated 
Numbers of genes 
down-regulated 
ASD-IS 
Vs. ASD/FPIES 
Vs. ASD/non-FPIES 
Vs. control 
 
 
2311 
784 
1341 
 
 
61 
1482 
617 
ASD/FPIES 
Vs. ASD/non-FPIES 
Vs. control 
 
 
251 
223 
 
922 
191 
ASD/non-FPIES 
Vs. control 
 
 
7233 
 
11523 
1CCR7 and CCL7 are up-regulated in ASD-IS monocytes as compared to ASD/FPIES monocytes (>2 
fold) 
2Transcripts of CCL3, IL-1ß, IL-23A, and IL-6 in ASD-IS monocytes were all down-regulated as 
compared to the ASD/non-FPIES monocytes (>2 fold).  Gene expression of IL-23A and IL-6 in 
ASD/FPIES monocytes were down regulated 6.4 and 4.9 fold, respectively, than ASD/non-FPIESPB 
monocytes. 
3As compared to normal controls, ASD/non-FPIES monocytes revealed up-regulation of IL-23A (5.4 
fold) as well down-regulation of CCL7 (chemockine- 5.4 fold). CCL7 expression was also down-
regulated as compared to ASD-IS as well as ASD/FPIES monocytes (>2 fold). 
Table 3. Transcription profiling data in the study subjects. 
4. Discussion 
FPIES was first reported in 1940’s and has been recognized as a relatively benign condition 
that shows good responses to avoidance measures. However, delayed onset of symptoms 
and lack of readily (commercially) available diagnostic measures hinders early diagnosis 
and early intervention. This is especially true for children with impaired expressive 
language, such as ASD children.  For example, it has been our observation that behavioral 
changes associated with GI discomfort and pain are often attributed to be just ‘being 
autistic’, despite presence of objective GI symptoms.  In previous years, we have attempted 
to sort out whether FPIES is prevalent in ASD children and if so, how FPIES affects their 
behavioral symptoms.  Our previous results indicated a high prevalence of FPIES in ASD 
children, probably partly due to delayed diagnosis and treatment (Jyonouchi, 2010; 
Jyonouchi H, 2007). We also observed changes of behaviors after resolution of GI symptoms 
when behavioral changes were assessed using the Aberrant Behavior Check list (ABC) 
(Jyonouchi, 2010; Jyonouchi H, 2007). 
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Group GO 
ID 
GO Term Corrected  
p value 
 
ASD-IS  
vs. ASD/FPIES 
3290 
3593 
8215 
8217 
Oxygen transporter activity 
Hemoglobin complex 
Gas transport 
Oxygen transport 
0.02578 
0.02578 
0.01368 
0.02578 
ASD-IS  
vs. ASD/non-
FPIES 
4528 
6431 
19583
Response to stress 
Response to wounding 
Positive regulation of cell adhesion 
0.06276 
0.06276 
0.02184 
ASD-IS  
vs. controls 
 
  NS 
ASD/FPIES  
vs. ASD/non-
FPIES 
 
801 
936 
1402 
1465 
3128 
3145 
3430 
4518 
4528 
4529 
4531 
4532 
5082 
5098 
5114 
6425 
6431 
7346 
10575
 
12106
13736
15920
16941
17002
17201
17250
19242
19243
 
19628
22266
22267
23421
23697
 
23761
23762
G-protin-coupled receptor binding 
Positive regulation of cytokine production 
Immune system process 
Chronic inflammatory response to antigenic stimulus 
Receptor binding 
Cytokine activity 
Extracellular space  
Chemotaxis 
Response to stress 
Defense response 
Inflammatory response 
Immune response 
Behavior 
Locomotry behavior 
Chemokine activity 
Response to external stimulus 
Response to wounding 
Regulation of vascular endotheial growth factor production 
Cytokine and chemokine mediated signaling pathway 
Nitric oxide transport 
Positive regulation of synaptic plasticity 
Positive regulation of heterotype cell-cell adhesion 
Regulation of cytokine biosynthetic process 
Positive regulation of cytokine biosynthetic process 
Taxis 
Chemokine receptor binding 
Regulation of nitric oxide biosynthetic process 
Positive regulation of nitric oxide biosynthetic process 
Positive regulation of mitosis 
Regulation of smooth muscle cell proliferation 
Positive regulation of smooth muscle cell proliferation 
Response to stimulus 
Positive regulation of nitrogen compound metabolic process 
Regulation of muticellular organismal process 
Positive regulation of muticellular organismal process 
0.06068 
0.06644 
0.03348 
0.05304 
0.05304 
3.75E-04 
0.03299 
0.00644 
2.43E-05 
2.45E-08 
2.14E-08 
3.75E-04 
0.05386 
0.03956 
0.00822 
1.25E-05 
2.15E-08 
0.06512 
0.03138 
 
0.05304 
0.05304 
0.05304 
0.05304 
0.05613 
0.00644 
0.00918 
0.06068 
0.03956 
 
0.05304 
0.03956 
0.00822 
0.07731 
0.05304 
 
0.05304 
0.03348 
Table 4. GO analysis results in the study subjects 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
380 
However, among ASD children with FPIES, there exists a subset of children who are also 
vulnerable to recurrent infection and have history of adverse reactions to multiple medications 
and other substances. These children are sensitive to a variety of food proteins and often 
require the intake of extremely hydrolyzed hypoallergic formulas to get sufficient nutrition, in 
our experience. Parents of these children also reports fluctuating behavioral symptoms and 
cognitive skills following immune insults, such as viral syndrome. Our previous studies 
indicated that these children, with fluctuating behaviors, often exhibit distinct innate immune 
abnormalities (Jyonouchi et al., 2008). Further analysis of this population led to the finding that 
ASD children with these clinical phenotypes, as well as ‘treatment-resistant’ FPIES, do reveal 
more significant changes in innate immunity which can be detected using bioassays as well as 
transcript profiles in PB monocytes (manuscript in press). We have categorized this group of 
ASD children as ASD-immune subtype (ASD-IS), since they appear to reveal different immune 
abnormalities than ASD/FPIES as well as ASD/non-FPIES children. These children also seem 
to be vulnerable to dysbiosis, since their GI symptoms, as well as behavioral symptoms, tend 
to improve following anti-fungal treatment and/or antibiosis targeting pathogenic microbes in 
the gut. Unfortunately, as reported by others (Sandler et al., 2000), these effects are generally 
transient.  
It remains unclear as to how such clinical phenotypes are associated with innate and 
adaptive immune responses and how their immune responses are different from those 
observed in ASD/FPIES and non-ASD/FPIES children. To address this question, we 
conducted detailed studies of innate and adaptive immune responses in ASD-IS children in 
comparison with ASD/FPIES, non-ASD/FPIES, ASD/non-FPIES, and normal controls. 
Since the presence of active GI inflammation is likely to affect the bioassay results, we 
conducted these assays after FPIES subjects were appropriately treated with avoidance 
measures and nutritional supplements if required. Co-morbid conditions summarized in 
Table 2 in our study groups revealed that ASD-IS children do seem to have a higher 
prevalence of COM/CRS than other study groups, although prevalence of atopic disorders 
does not appear to be altered significantly among the study groups, indicating that atopy or 
Th2 deviated responses are unlikely to be associated with their clinical characteristics. 
When we assessed innate immune responses in the study groups, our results revealed lower 
TNF-ǂ and IL-12 production with a TLR4 agonist (LPS) than normal controls in the 
ASD/FPIES group. In the colon where microbes reside at the highest concentration, 
responses to endotoxin such as LPS are suppressed – so-called LPS desensitization (Abreu et 
al., 2005; Michalek et al., 1982; Smith and Nagler-Anderson, 2005; Wannemuehler et al., 
1982). Tendency for lower responses to LPS in ASD/FPIES children may be beneficial for 
maintaining oral tolerance after recovering from FPIES. Although it was not significant, the 
same tendency was observed in non-ASD/FPIES children.  
In ASD-IS children, while their LPS responses are equivalent to those of normal controls, 
spontaneous production of IL-1ß and IL-12 production with a TLR9 agonist was markedly 
lower. IL-1ß production with a dectin 1 agonist (heat killed candida) was also lower in the 
ASD-IS children. Lower production of IL-6 (without stimuli and with TLR9 agonist) and IL-
23 (with a TLR4 agonist) were observed in both ASD/FPIES and ASD-IS children but this 
was more evident in ASD-IS children. On the other hand, non-ASD/FPIES children were 
noted to have higher TGF-ß with a TLR2/6 agonist (zymosan). IL-1ß, IL-6, and IL-23 are all 
important for differentiation and maintenance of Th17 cells as a part of their pleiotropic 
biological actions (Kimura and Kishimoto, 2010; Zhou et al., 2009). While IL-12 has a key 
role in Th1 cell differentiation. Given these findings, it may be questioned whether ASD-IS, 
as well as ASD/FPIES children, have impaired development of Th17 cells. When we tested 
frequency of IL-17+ Th cells after stimulation of PBMCs with SEB overnight, frequency of 
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Th17 cells was lower in ASD/FPIES children than normal controls, but this was not evident 
in the ASD-IS children. Both ASD-IS and ASD/FPIES children revealed a little lower 
frequency of IFN-Ǆ+ Th1 cells. However, to our surprise, IL-17 production in response to 
food proteins was higher in the ASD-IS children. Comparative frequency of Th17 cells, but 
higher IL-17 production in the ASD-IS children indicate that committed Th17 cells may keep 
producing a large amount of IL-17. These findings also indicate that excessive IL-17 
responses in ASD-IS children may be associated with dysregulated development and 
maintenance of Th17 cells. In addition, persistent IL-17 responses will not aid in and may 
hinder establishment of gut immune homeostasis consistent with clinical phenotype of 
‘treatment-resistant’ FPIES in the ASD-IS children.  
In contrast to the ASD-IS group, non-ASD/FPIES children recovering from FPIES revealed 
higher TGF-ß with a TLR2/6 agonist (zymosan). These children did not reveal an increase in 
frequency of Th17 cells or IL-17 production. Since TGF-ß regulates (down-regulates) various 
immune responses and also serves as a key differentiation factor for regulatory T (Treg) 
cells, especially in the absence of inflammatory cytokines (Burgler et al., 2009; Zhou et al., 
2009), it may be wondered whether ASD-IS children and in some-degree, ASD/FPIES 
children have impaired development or function of regulatory T cells. In the GI mucosa, IL-
10 and TGF-ß producing Treg cells are believed to have a major role in the gut immune 
homeostasis (Lee and Mazmanian, 2010). In that regard, non-ASD/FPIES children and 
perhaps ASD/FPIES children who did not reveal excessive IL-17 responses may be in the 
process of establishing gut mucosal immune homeostasis, while recovering from FPIES.  
In the gut mucosa, it became known that Th17 cell develop prior to antigen exposure, 
bearing an important role in mucosal immune defense. However, following antigen-
exposure, regulatory T cells develops, developing immune homeostasis in the gut. During 
this process, the gut microbiota is believed to have an pivotal role in developing gut 
immune homeostasis affecting plasticity of Th cell and regulatory T cell development 
(Atarashi et al., 2011; Lee and Mazmanian, 2010; Lochner et al., 2011; Zhou et al., 2009). 
Consistent with this assumption, we also found that spontaneous IL-10 production, as well 
as that in response to luminal antigens (food proteins and candida Ag), were equivalent in 
non-ASD/FPIES children in comparison with normal controls. While ASD-IS children 
revealed lower IL-10 production, in the absence of stimuli and with candida Ag. These 
results again indicate that tolerance induction or establishment of immune homeostasis may 
be impaired in the ASD-IS children. However, it needs to be cautioned that further studies 
are necessary to explore this possibility, including testing gut mucosal expression of Th 
lineage cells in these patients. As previously stated, ASD-IS children are clinically 
characterized with markedly fluctuating behavioral and cognitive activity. Our findings also 
indicate the possibility that in addition to impairment of gut immune homeostasis, systemic 
immune homeostasis may also be dysregulated in the ASD-IS children. This may be the 
results of chronic gut inflammation or uncontrolled inflammatory responses. 
To further assess changes in innate immunity, we also studies transcript profiles of PB 
monocytes in the study groups. However, partly due to the restriction of approved protocol, 
we were not able to conduct such a study in the non-ASD/FPIES children. Nevertheless, our 
results indicated a significantly altered gene expression in PB macrophages in the ASD-IS 
children. The numbers of genes with >2 fold up- or down-regulated expression was the 
highest when compared to normal controls and least when compared to ASD/FPIES 
children. This is not surprising, given the fact that ASD-IS and ASD/FPIES children both 
suffered from FPIES and gut inflammation. However, what was surprising is that the 
significant differences in transcript profiles of PB monocytes between ASD/non-FPIES and 
normal controls. These results also indicate that ASD/non-FPIES children may have altered 
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immune responses or other changes that can be reflected in PB monocytes. This seems to be 
consistent with the results of the GO analysis, which revealed significant changes between 
ASD/FPIES and ASD/non-FPIES children. Involved pathways revealed differences with 
GO analysis are largely associated with immune/inflammatory responses as well as 
cytokines and chemokines, possibly reflecting fundamental differences in the 2 study 
groups. It should be noted that recent genetic studies have been accumulating evidence that 
ASD is a behavioral syndrome encompassing markedly heterogeneous populations (Bale et 
al., 2010; Rudan, 2010; Toro et al., 2010). Our findings also support results of previous 
genetic studies. However, we have to be cautious about the results given the low number of 
study subjects that underwent this analysis. 
With transcription profiling, we also found that certain cytokines, notably IL-6, IL-1ß, and 
IL-23, were down regulated in ASD-IS children, as compared to ASD/non-FPIES children. 
ASD/FPIES children also revealed down-regulation of IL-6 and IL-23. Interestingly, down-
regulation of IL-6 was more prominent in ASD/FPIES children, despite the fact that in vitro 
IL-6 protein production was lower in the ASD-IS children. In addition, GO analysis revealed 
significant differences between ASD/FPIES and ASD/non-FPIES groups, although given 
clinical features, one can expect that differences may be more prominent between ASD/IS 
and ASD/non-FPIES children. Our findings may indicate an importance of post-
transcriptional regulation including ones exerted by microRNA (Baltimore et al., 2008).  
The notable weakness of this study is lack of data of transcription profiling in the non-
ASD/FPIES children. This was secondary to the restriction imposed by the IRB and lack of 
funding. In the future, it will be interesting to compare transcript profiles between ASD-
IS/ASD-FPIES and non-ASD/FPIES children which may yield further important information. 
5. Conclusion 
In summary, our results indicate that altered adaptive and innate immune responses are 
observed in both ASD-IS and ASD/FPIES children but difference exist between the ASD-IS 
and ASD/FPIES children. In addition, these changes also differed from those observed in 
non-ASD/FPIES children. Our findings thus indicate that changes in innate and adaptive 
immunity observed in ASD-IS children and in some degree even in ASD/FPIES children, 
are not likely to be attributed to FPIES but may be associated with impaired establishment 
of immune homeostasis, perhaps, affected by aberrant innate immune responses.  
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